Doctors are vital players in the welfare of the entire society. They put in rigorous and long work hours, follow tough schedules, and make their patients their priorities -for this they should be highly appreciated and recognized. This is indeed what the National Doctors' Day is all about. It is also a day to reflect and contemplate on the changing scenario. It is essential for the doctors to make efforts to reestablish the lost trust. Professional organizations, health care authorities, and government must map out strategies to assist doctors in rebuilding this trust. They must also implement clear laws for health care professionals to abide by. These steps are essential to take to improve the health care industry in India. Here's hoping on this National Doctors' Day that medical profession restores the glory that it enjoyed in the golden era in the coming future. Let us make the required changes in our fraternity and our practices, before the situation gets any worse. All of us should also actively take steps to improve the image of the medical profession, because none of us is above this collective perception.
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using 5% cefuroxime, a second-generation cephalosporin. Cefuroxime-gentamicin has been reported to be equivalent to cefazolin-tobramycin or moxifloxacin in treating bacterial keratitis in one study [4] and ofloxacin in another study. [5] However, topical cefuroxime is not widely used in India like cefazolin.
We retrospectively reviewed medical records of 21 consecutive patients with GPBK treated with 5% cefuroxime from November 2017 to January 2018 and compared the outcome with another cohort of 54 consecutive patients with GPBK treated with 5% cefazolin from April to August 2017. The Institute Ethics Committee approval was taken for the study.
Both groups exhibited similar baseline characteristics [ Table 1 ], except for the higher proportion of males in the cefazolin-treated group (P = 0.04). There was no statistically significant difference in outcome, resolution time, or posttreatment visual acuity *5% cefuroxime was prepared by dissolving two vials of cefuroxime sodium IP 250 mg (Cetil ® , Lupin Ltd., Mumbai) in 2 ml of sterile water for injection each, and then adding 4 ml of this solution to 6 ml of artificial tears (Tears Plus ® eye drop, Allergan India Pvt. Ltd., Bengaluru), † 5% cefazolin was prepared by dissolving cefazolin sodium IP 500 mg (Reflin®, Ranbaxy Lab. Ltd., Gurugram) in 2 ml of sterile water for injection and then adding this solution to 8 ml of artificial tears.
The dosing schedule of these topical antibiotics and other adjunct medications was as per standard guidelines [1] , ‡ Z-test for proportion, § Unpaired Student t-test, II Visual acuity could not be measured in one eye in Group A and two eyes in Group B, ¶ One patient had polymicrobial infection in Group A, hence total number of isolates is 22. LogMAR: Log of the minimum angle of resolution between the two groups [ Table 2 ]. 5% cefuroxime topical preparation remained stable for 5-7 days in room temperature, and no ocular toxicity was seen.
There are limitations in our study. This is not a randomized control trial, with a head-to-head comparison of cefuroxime and cefazolin, but a comparison with a historical cohort of patients treated with cefazolin. While such a trial would be desirable, in this case, the unavailability of cefazolin makes it impossible to carry out such a study. This study's intention is only to inform ophthalmologists of the potential of cefuroxime to be a viable and safe alternative to cefazolin, and drugs like vancomycin can be held in reserve. Larger controlled trials comparing cefuroxime to vancomycin or fourth-generation fluoroquinolones are required to support our findings. As these trials take considerably more time and resources, we believe that in the interim, our findings should provide useful direction in treating GPBK in India.
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C o m m e n t a r y o n " I n t r a v i t r e a l d e x a m e t h a s o n e i m p l a n t f o r management of treatment-naïve retinal vein occlusion"
Sir, Treatment of macular edema has been revolutionized by the introduction of optical coherence tomography and intravitreal injections over the last decade and a half. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, initially introduced for neovascular Age-related macular degeneration have made a significant contribution toward alleviating macular edema due to diabetes and retinal vein occlusion (RVO). Corticosteroid injections have been used in the past. Introduction of intravitreal dexamethasone implant (IDI) just under a decade back, has added to the armamentarium of the ophthalmologist. It provides sustained released dexamethasone, typically over a period of 3-6 months, reducing the need for frequent injections. However, it is accompanied by the increased chances of intraocular pressure (IOP) rise, and progression/onset of cataract.
The article "The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario" [1] addresses an important question. In this article, the authors have shared their experience with the use of IDI in eyes with macular edema secondary to RVO, which have not received any other prior treatment. While most literature and current practice focuses using IDI as alternate therapy in eyes not responding to anti-VEGF injections, the question addressed here is, whether IDI can be offered as a primary therapy.
To address this question, let us list out certain salient points. Mechanism of macular edema is multi-factorial. While most anti-VEGF agents target limited factors, steroid agents have anti-angiogenic, anti-inflammatory, and anti-proliferative effects. The incidence of adverse events with IDI, ranges from 6% to 32% for cataract (needing surgery), and 5%-36% for IOP rise (>25 mm Hg needing IOP lowering drugs). [2, 3] None of these studies mention need for glaucoma surgery for IOP management. To add, these adverse events, occur at a lower frequency with IDI, as compared to other steroid injections. [4] This could possibly be due to different ocular distribution [5] and pharmacological profile [6] of various corticosteroids. In all series, management of IOP rise was by IOP lowering medication, and cataract was very safely managed with cataract surgery. The results and inferences from previously published literature are in agreement with this study, and our own experience. In comparison, the ocular safety profile of anti-VEGF injections is generally favorable. However, they have been reported to be associated with increased risk of cerebrovascular accidents [7] and myocardial infarction (MI). [8] A sustained release drug, decrease number of injections and hence burden of therapy. When using dexamethasone implant, overall cost of treatment may actually come down for the patient, when compared to most anti-VEGFs (except off-label use of bevacizumab) as frequent injections are not required. Often there may be patient/family anxiety associated with repeated injections. Lesser visits to operating room/injection room, with use of sustained release drug help alleviate patient anxiety.
Therefore, as a concluding remark, it might be most prudent to offer the choice of treatment to the patient. Allowing them to make an informed choice. Explaining risks and benefits of each. Certain existing patients' conditions, as mentioned above may not be suitable, for example, existing glaucoma for steroid use, and known history of transient ischemic attacks, stroke, and MI for anti-VEGF use. For the rest, it may be most wise to give the choice to the patient and make an informed choice ourselves as well, as treating surgeons.
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